Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020


 

Treatment Options for Young "Fit" (FCR Eligible) CLL Pts: Ibrutinib/Rituximab Improve PFS and OS & iFCG Regimen Effective for Pts With IGHV-Mutated CLL

76 views
March 4, 2020
0 Comments
Login to view comments. Click here to Login
Malignant Hematology